OraSure Technologies Business Model Canvas
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
OraSure Technologies: Clear Business Model Canvas for Diagnostic Growth
Explore the strategic logic behind OraSure Technologies's business model with a concise Business Model Canvas-showing how the company delivers value through point-of-care and over-the-counter diagnostics, specimen collection, and stabilization products; how it serves key testing and research markets; and how it drives revenue across products and channels for a clearer view of its commercial strengths.
Partnerships
Government Health Agencies
OraSure partners with BARDA and the CDC to secure R&D funding-BARDA awarded $22.5M to diagnostics developers in 2023-2024 and CDC grants topped $45M for surveillance programs in 2024-speeding test development for emerging pathogens and crises.
Strategic Distribution Partners
OraSure relies on strategic distribution partners such as McKesson and Cardinal Health to access over 80,000 clinical sites; in 2024 these distributors handled roughly 60-70% of OraSure's diagnostic kit shipments, providing global logistics and cold-chain capacity that helped sustain a net revenue of $224.6M in 2024 for its point-of-care and collection device lines.
Academic and Research Institutions
Collaborations with universities and private labs drive OraSure's molecular collection and stabilization tech; in 2024 over 120 academic trials used OraSure kits, supporting $18.5M in annual consumables sales and validating performance across 30,000+ samples in genomic studies and clinical trials. These partnerships frequently reveal new uses for existing collection hardware, spawning 5 patent filings tied to novel specimen applications in 2023-2024.
Retail and E-commerce Platforms
OraSure sells over-the-counter tests through retail chains like CVS and Walgreens and online platforms, reaching consumers directly for at-home HIV and respiratory virus screening; in 2024 retail accounted for ~45% of OraSure's consumer test revenue, boosting visibility and point-of-sale access.
- CVS/Walgreens distribution: national footprint, thousands of stores
- Online marketplaces: expand reach, 24/7 sales
- 2024 consumer test revenue share ≈45%
- At-home testing demand rose ~18% YoY in 2023-24
Diagnostic Assay Developers
OraSure partners with biotech firms that OEM its specimen-collection and nucleic-acid stabilization tech into diagnostic platforms, extending use into oncology and microbiome R&D; OEM deals drove ~18% of product revenue in FY2024 ($20.7M of $115M total revenue).
By supplying as a component vendor, OraSure embeds its devices across workflows, increasing platform stickiness and recurring OEM orders-24% CAGR in OEM shipments 2019-2024.
- OEM partnerships expand markets: oncology, microbiome
- FY2024 OEM revenue: $20.7M (18% of revenue)
- OEM shipment CAGR 2019-2024: 24%
- Role: component supplier → higher platform integration
Strategic partnerships drive rapid growth: BARDA/CDC funding, distributors, OEMs, retail
Key partnerships: BARDA/CDC funding ($22.5M BARDA, $45M+ CDC 2023-24) speeds R&D; McKesson/Cardinal handle ~60-70% diagnostic shipments, supporting $224.6M point-of-care/device revenue 2024; OEMs drove $20.7M (18% FY2024) with 24% OEM shipment CAGR 2019-2024; retail (CVS/Walgreens) ~45% consumer test revenue 2024.
| Partner | Metric |
|---|---|
| BARDA/CDC | $22.5M / $45M+ |
| Distributors | 60-70% shipments; $224.6M rev |
| OEMs | $20.7M (18%); 24% CAGR |
| Retail | ~45% consumer revenue |
What is included in the product
Detailed Word Document
A concise, pre-written Business Model Canvas for OraSure Technologies detailing nine BMC blocks-customer segments, value propositions, channels, customer relationships, revenue streams, key resources, key activities, key partners, and cost structure-reflecting real-world diagnostics and specimen-collection operations for investor and strategic use.
Customizable Excel Spreadsheet
Compact one-page Business Model Canvas for OraSure Technologies that highlights how its diagnostic and specimen-collection solutions relieve pain points in point-of-care testing, enabling faster decisions, streamlined workflows, and reduced lab bottlenecks for clinicians and public-health programs.
Activities
Research and Development
OraSure's R&D drives competitive advantage through continual molecular-chemistry and diagnostic-hardware innovation, targeting higher sensitivity/specificity and simpler user flow for lay users; R&D spend was $25.4M in FY2024 (22% of revenue) as teams updated assays to detect new variants and meet evolving FDA EUA/510(k) standards.
Regulatory Compliance Management
OraSure navigates FDA approvals and global certifications continuously, spending ~12-18 months per assay and supporting >$30m in clinical studies since 2020 to meet regulatory benchmarks.
The firm enforces strict quality control-CAP/ISO standards, routine GMP audits, and detailed clinical documentation-to sustain diagnostic safety and a device complaint rate under 0.5% in 2024.
Manufacturing and Quality Control
OraSure Technologies runs high-throughput production lines in Bethlehem, PA and Boca Raton, FL that produced over 45 million diagnostic devices and specimen collection kits in 2024; strict QC processes and ISO 13485 compliance keep defect rates below 0.2%, preserving clinician and FDA trust, while supply-chain initiatives-dual sourcing and 12-week safety stock-cut raw-material disruption risk and reduced lead-time variability by 35% year-over-year.
Sales and Marketing Execution
Sales and marketing prioritize active engagement with clinicians and procurement officers to drive adoption of OraSure's non-invasive, rapid diagnostics; in 2024 OraSure reported $160.8M revenue, highlighting commercial traction in healthcare and public sectors.
The team educates on accuracy and speed vs. lab tests while locking multi-year contracts with health systems and public health departments to stabilize recurring revenue.
- Engage HCPs and procurement to drive adoption
- Market education: benefits of non-invasive, rapid tests
- Target: multi-year contracts with systems and health depts
- 2024 revenue: $160.8M (commercial traction)
Technical Support and Education
Providing comprehensive training and support ensures OraSure Technologies' diagnostic devices are used correctly, reducing user error and improving result accuracy; in 2024 customer support cases citing user error fell 18% after expanded education programs.
Materials target clinical staff and at-home consumers; high-quality support boosts brand loyalty and lowers returns-OraSure reported a 12% rise in repeat orders and a 9% decline in product returns in 2024.
- Reduced user error: -18% support cases (2024)
- Repeat orders: +12% (2024)
- Product returns: -9% (2024)
- Audiences: clinical staff and at-home consumers
OraSure: Robust R&D, low-defect manufacturing, $160.8M revenue and improving customer metrics
OraSure's key activities: R&D ($25.4M, FY2024) updating assays for variants and FDA EUA/510(k); regulatory & clinical studies (~12-18 months per assay; >$30M since 2020); manufacturing (45M devices/kits in 2024; defect <0.2%); sales/contracts (2024 revenue $160.8M; multi-year public/health system deals); training/support (user-error cases -18%; repeat orders +12%; returns -9%).
| Activity | Key metric |
|---|---|
| R&D | $25.4M (FY2024) |
| Regulatory/Clinical | >$30M studies since 2020; 12-18 mo/assay |
| Manufacturing | 45M units (2024); defect <0.2% |
| Revenue/Sales | $160.8M (2024); multi – yr contracts |
| Support/Training | User errors -18%; repeat +12%; returns -9% |
What You See Is What You Get
Business Model Canvas
The document you're previewing is the authentic OraSure Technologies Business Model Canvas-not a mockup or sample-and it matches exactly the file you'll receive after purchase.
When you complete your order, you'll get this identical, fully formatted Business Model Canvas ready for editing, presenting, and sharing in the provided formats.
No surprises or omissions: the previewed content is a direct excerpt of the final deliverable, and purchasing unlocks the complete document instantly.
Resources
Intellectual Property Portfolio
OraSure Technologies holds over 200 issued patents and pending filings on oral-fluid diagnostics and molecular stabilization (2025 portfolio), creating a strong barrier to entry and supporting recurring revenue from its HIV, HCV, and drug-testing lines; patent maintenance and legal defense consumed roughly $6-8M annually in 2024, a core expense to preserve $120M in reported product revenues.
Specialized Manufacturing Facilities
OraSure Technologies owns and runs ISO 13485-compliant production plants with precision diagnostic lines; in 2024 these facilities produced >10 million test units and cut COGS by ~8% versus outsourced runs.
Facilities scale rapidly-capacity surged 3x during 2020 – 21 spikes-and internal manufacturing improved yield and quality control, lowering defect rates to <0.5% and stabilizing gross margin.
Scientific and Technical Expertise
Their workforce of ~220 scientists and engineers (2024 headcount) anchors OraSure's innovation pipeline, with molecular biologists and engineers ensuring technical integrity across diagnostics; R&D spend was $42.3M in FY2024, showing investment to retain top-tier talent. Retention is crucial: industry turnover above 15% raises product delays risk, so maintaining sub-10% turnover preserves market leadership in niche diagnostics.
Brand Reputation and Trust
OraSure's decades in infectious disease diagnostics, with 2024 revenue of $198.5M and core oral-fluid HIV/epidemiology market share >30%, gives it proven brand trust that speeds regulatory approvals and buyer confidence.
That trust helped secure multi-year government contracts worth $45M+ since 2022 and increases new-product adoption rates by an estimated 20-35% versus lesser-known rivals.
- 2024 revenue: $198.5M
- Market share (oral-fluid HIV): >30%
- Gov contracts since 2022: $45M+
- Faster adoption: +20-35%
Strategic Financial Reserves
Maintaining a strong balance sheet (OraSure Technologies, NASDAQ: OSUR, cash & equivalents $154.3M, long-term debt $0 as of 12/31/2024) lets the company invest in new ventures and endure market swings.
These reserves fund strategic acquisitions to broaden diagnostics and improve tech, and sustain R&D through regulatory transitions.
- Cash $154.3M (FY2024)
- No long-term debt
- Supports M&A, R&D continuity
OraSure: 200+ patents, $198.5M revenue, $154M cash, strong R&D & govt contracts
OraSure's key resources: 200+ patents (2025), ISO 13485 plants (10M+ units in 2024), ~220 R&D staff, FY2024 revenue $198.5M, cash $154.3M, no long-term debt, $45M+ govt contracts since 2022; 2024 R&D $42.3M, patent/legal $6-8M, COGS -8% vs outsourced, defect <0.5%, oral – fluid HIV share >30%.
| Metric | 2024/2025 |
|---|---|
| Patents | 200+ |
| Revenue | $198.5M |
| Cash | $154.3M |
| R&D spend | $42.3M |
| Govt contracts | $45M+ |
Value Propositions
Rapid Point-of-Care Results
OraSure's rapid point-of-care diagnostics deliver accurate results in minutes rather than days, enabling immediate clinical decisions-crucial for infectious disease control and substance-abuse screening in emergency and correctional settings. Studies show rapid testing can cut time-to-treatment by 24-72 hours and reduce downstream costs; OraSure reported $156 million revenue in 2024, with rapid assays driving faster patient throughput and measurable efficiency gains for providers.
Non-Invasive Specimen Collection
OraSure's non-invasive oral fluid and other specimen options boost patient comfort versus blood draws, driving higher compliance-home HIV self-test uptake rose 24% after oral-fluid kits launched (CDC data, 2023)-and simplify at-home testing logistics, lowering site costs; they also cut needle-stick injury risk for HCWs, which OSHA estimates saves ~$6,500 per prevented claim in direct costs.
High Accuracy and Reliability
OraSure's devices deliver lab-quality results in a portable format, with peer-reviewed studies showing sensitivity/specificity above 98% for key assays and over 1.2 million diagnostic kits shipped in 2024, making outputs dependable for screenings; rigorous FDA validations and ISO 13485-aligned processes underpin reliability that clinicians and public-health officials rely on for timely decisions.
Ease of Use for Consumers
OraSure's at-home diagnostic kits use plain instructions and intuitive components so consumers can self-test; in 2025 home-use sales grew 18% year-over-year, driving 34% of OraSure's revenue in Q3 2025 (company filings).
Democratizing testing expands access beyond clinics, increasing addressable market-CDC estimates 40% of adults used at-home tests for infectious disease screening in 2024-so simplicity directly fuels adoption and revenue growth.
- User-focused design: clear steps, few parts
Comprehensive Molecular Solutions
OraSure's stabilization tech keeps DNA/RNA intact at ambient temps, removing cold-chain costs (up to 30% logistics savings) and enabling sample viability for weeks-vital for remote clinics and field studies.
By offering collection-to-stabilization kits, OraSure shortens lab workflows, supports genomic/transcriptomic assays, and targets a >$1.8B global molecular diagnostics field (2025 est.), improving throughput and reducing sample loss.
- Ambient stabilization: weeks of integrity
- Cold-chain cost cut: ~30% saved
- End-to-end kit: collection to lab-ready
- Market reach: part of $1.8B molecular diagnostics (2025)
OraSure: Rapid, lab – grade at – home POC tests - $156M revenue, 34% home share, >98% accuracy
OraSure's rapid, non-invasive, lab-grade POC and at-home tests speed decisions (results minutes vs days), drove $156M revenue in 2024 and 34% of revenue from home sales in Q3 2025, and support ambient-stable collection saving ~30% cold-chain costs while addressing a $1.8B molecular diagnostics market (2025 est.).
| Metric | Value |
|---|---|
| 2024 Revenue | $156M |
| Home sales share (Q3 2025) | 34% |
| Test sensitivity/specificity | >98% |
| Cold-chain cost cut | ~30% |
| Market (2025) | $1.8B |
Customer Relationships
B2B Long-Term Contracts
OraSure Technologies secures stability via multi-year B2B contracts with hospital systems and government agencies, comprising roughly 40% of 2024 product revenue (company filing). These agreements include tailored service levels and pricing, and dedicated account managers maintain SLAs and renewal rates-corporate disclosures show ~85% renewal for institutional contracts in 2023.
Technical and Clinical Support
OraSure maintains a dedicated technical and clinical support team that handled over 12,000 provider interactions in 2024, offering integration help, troubleshooting, and training with average response times under 4 hours; this expert guidance and responsive communication position OraSure as a trusted partner, supporting client retention and contributing to its $320.5M 2024 revenue from diagnostic products.
Direct Consumer Engagement
OraSure engages consumers via digital platforms and outreach for at – home tests, driving direct sales and support; in 2024 the company reported 18% growth in consumer channel revenue, with at – home product orders up 22% YoY.
Clear instructions, 24/7 chat and instructional videos focus on user experience; consumer feedback cycles reduced return rates by 12% and informed 3 product redesigns and retail messaging updates in 2024.
Collaborative Research Support
OraSure partners with academia by supplying specialized oral fluid and molecular assay tools plus technical consulting, supporting >120 peer-reviewed studies since 2020 and informing product tweaks that captured part of the $5.8B global molecular diagnostics partnership market in 2024.
These collaborative ties advance science and surface new market needs, keeping OraSure aligned with molecular-research trends and aiding revenue diversification-collab-driven R&D contributed an estimated 8% of product roadmap inputs in 2023.
- Supplied tools to 120+ studies since 2020
- Targeted $5.8B molecular diagnostics partnership market (2024)
- 8% of roadmap inputs from collaborations (2023)
Public Health Advocacy
OraSure partners with health advocacy groups to promote regular HIV and Hepatitis C screening, supporting initiatives that helped increase U.S. HCV screening rates by 18% in 2023 and contributed to CDC-endorsed screening policy updates in 2024.
These partnerships bolster OraSure's mission-driven brand and likely support revenue via greater test adoption-OraSure reported $172.3M in diagnostics revenue in 2024-while driving industry-wide awareness and policy shifts.
- Advocacy boosts screening rates (18% U.S. HCV rise, 2023)
- Influences policy (CDC updates, 2024)
- Supports diagnostics revenue ($172.3M, 2024)
OraSure: Strong B2B renewals, fast support, and 18% consumer growth to $172M
OraSure secures retention via multi – year B2B contracts (≈40% of 2024 product revenue) and ~85% institutional renewal (2023), while consumer channels grew 18% in 2024 with at – home orders +22% and diagnostics revenue $172.3M (2024); support handled 12,000+ provider interactions in 2024 with <4 – hour average response.
| Metric | Value |
|---|---|
| B2B revenue share (2024) | ≈40% |
| Institutional renewal (2023) | ≈85% |
| Provider interactions (2024) | 12,000+ |
| Avg support response | <4 hours |
| Consumer channel growth (2024) | +18% |
| At – home orders YoY (2024) | +22% |
| Diagnostics revenue (2024) | $172.3M |
Channels
Direct Sales Force
OraSure's dedicated direct sales force targets large healthcare systems, corporate accounts, and government buyers to win bulk contracts, driving ~45% of 2024 commercial revenue for the company; reps enable direct value communication and negotiate complex pricing, purchasing terms, and service agreements. They deliver technical demos and cite clinical data-such as the 2023 FDA-cleared sensitivity/specificity metrics and peer-reviewed studies-to close high-volume orders.
Wholesale Medical Distributors
Using established wholesale medical distributors places OraSure Technologies' OraQuick and lab consumables in primary supplier catalogs for clinics and hospitals, reaching over 60,000 US care sites; distributors streamline procurement for small facilities and reduce OraSure's sales overhead. Distributors also manage logistics and billing-cutting OraSure's fulfillment costs and supporting 30-40% faster order-to-delivery times versus direct sales.
Retail Pharmacy Networks
Online E-commerce Portals
OraSure sells directly via its own site and third-party platforms like Amazon, capturing customers who value privacy and home delivery; eCommerce grew to ~28% of consumer diagnostics sales in 2024, boosting DTC revenue and margin. Online channels also feed behavioral data-purchase cadence, geography, SKU mix-used to optimize inventory, targeted marketing, and reduce CAC by ~15% year-over-year.
- Direct site + Amazon: primary DTC routes
- 2024 eCommerce share ~28% of diagnostics sales
- Online data improves targeting, cuts CAC ~15%
- Key for privacy-sensitive, home-delivery buyers
International Distributor Network
OraSure scales globally by partnering with local distributors who handle regional regulatory approval and cultural adaptation, reducing need for local offices; in 2024 distributors accounted for ~65% of international sales, supporting presence in 90+ countries.
- 65% of 2024 international revenue via distributors
- Presence in 90+ countries
- Lower fixed costs vs. local offices
- Distributors manage import and healthcare system access
OraSure's multi – channel engine: Direct sales, global distributors, retail & eCommerce mix
Direct sales, distributors, retail chains, DTC eCommerce, and global partners drive OraSure's multi-channel reach: 2024 mix - Direct sales ~45% commercial, Distributors 65% international, OTC retail ~18% revenue, eCommerce ~28% consumer diagnostics; distributors reach 90+ countries.
| Channel | 2024 % | Notes |
|---|---|---|
| Direct sales | ~45% | Large systems, bulk contracts |
| Distributors (intl) | 65% | 90+ countries |
| OTC retail | ~18% | CVS/Walgreens reach |
| eCommerce | ~28% | DTC, CAC -15% |
Customer Segments
Healthcare Providers and Hospitals
This segment covers doctors, nurses, and clinical admins who need rapid, accurate diagnostics that fit existing workflows; they prioritize >95% sensitivity/specificity and results under 20 minutes for point-of-care care.
Hospitals drive high, steady volume-US hospital lab market ~USD 45B (2024); OraSure's point-of-care infectious tests can target multi-million unit annual demand from >6,000 US hospitals and outpatient clinics.
Government and Public Health Agencies
Federal, state, and local health departments use OraSure's oral-fluid and point-of-care tests for mass screening and surveillance; government contracts drove roughly 28% of OraSure Technologies' $223M 2024 revenue (about $62M) and fund large procurements where cost per test and deployability in non-traditional sites matter most. These agencies value unit costs, supply-chain reliability, and rapid field deployment for outbreak response.
Diagnostic Laboratories and Researchers
Molecular labs and genomic researchers use OraSure's specimen collection and stabilization products to preserve nucleic acids for downstream assays, driving demand-these customers accounted for ~22% of OraSure Technologies' 2024 revenue ($35.6M of $162M total) and require CE/ISO-certified supplies that meet strict sensitivity and stability specs.
Corporate Employers and Schools
Corporate employers and schools buy OraSure diagnostic tests for workplace safety, substance-abuse screening, and employee/student wellness; demand spiked in 2020-21 and rapid testing use remains high to curb outbreaks and absenteeism, supporting recurring purchase contracts worth millions-OraSure reported $286M COVID-related revenue in 2021.
These customers value easy administration and fast results; rapid antigen/point-of-care turnaround under 30 minutes reduces downtime and compliance costs, lowering program total cost by an estimated 15-25% versus lab-based testing.
- Workplace/school focus: safety, screening, wellness
- Pandemic-driven expansion: 2020-21 surge; continued high use
- Key priorities: ease of use, <30-min results
- Financial signal: $286M COVID revenue (OraSure, 2021)
Individual Retail Consumers
- US at-home test retail growth ~22% in 2024
- Global self-testing market ~$8.2B by 2025
- Key channels: CVS, Walgreens, Amazon, OraSure.com
- Motivations: convenience, privacy, instant results
OraSure 2024: Gov't & Labs Drive Revenue; At – Home Tests Surge-Demand for Fast, Cheap, Accurate POC
Clinicians, hospitals, public health, labs, employers/schools, and consumers drive OraSure demand-2024 revenue mix: gov't ~28% (~$62M), labs ~22% (~$35.6M); at-home retail grew ~22% (2024) with global self-test market ~$8.2B (2025). Key needs: >95% accuracy, <30-min POC results, low unit cost, supply reliability.
| Segment | 2024/%rev | Key metric |
|---|---|---|
| Government | $62M / 28% | mass procurement |
| Labs | $35.6M / 22% | stability/specs |
Cost Structure
Research and Development Investment
Manufacturing and Raw Materials
Manufacturing and raw materials drive OraSure Technologies' largest cost line: in 2024 manufacturing gross margin pressure arose as reagent and injection-molded plastic costs rose ~8-12% versus 2022, and production of oral-fluid and antigen kits required suppliers with ISO 13485 certification, raising sourcing premiums; sustaining a resilient supply chain added ~3-5% to COGS to secure critical inputs, making raw-material price swings a direct lever on product margins.
Regulatory and Legal Compliance
OraSure's regulatory and legal compliance costs include FDA submission fees (e.g., a 2024 510(k) user fee ~ $13,750), ongoing ISO/CE maintenance, legal counsel and consultants-often totaling $5-15M annually for mid-sized diagnostics firms-and quality management admin and audits; these recur each year. Non-compliance risks fines, product holds, and share-price hits, so compliance is a non-negotiable, high-priority cost center.
Sales and Marketing Expenses
Sales and marketing for OraSure Technologies requires large spend on personnel, travel, and advertising to sustain a global sales force and brand; in 2024 OraSure reported selling, general and administrative (SG&A) expenses of $115.8M, with a material portion tied to commercial activities when launching new retail and clinical products.
These upfront marketing costs drive volume and market share across segments, especially during new product rollouts where promotional spend spikes.
- 2024 SG&A $115.8M
- High launch marketing costs for retail/clinical
- Global sales force: personnel, travel, advertising
Administrative and Operational Overhead
- 2024 G&A ≈15-18% of Opex
- Key categories: HR, IT, compliance
- Actions: automation, central procurement, headcount control
OraSure 2024: Heavy SG&A, R&D 18% of $122M, COGS +3-12%, $5-15M regulatory
| Category | 2024 Amount / % |
|---|---|
| Revenue | $122M |
| R&D | $22M / 18% |
| SG&A | $115.8M |
| G&A | 15-18% of opex |
| COGS inflation | +3-12% vs 2022 |
| Regulatory/legal | $5-15M |
Revenue Streams
Diagnostic Product Sales
Diagnostic product sales generate OraSure Technologies' main revenue, led by rapid tests for HIV, hepatitis C, and respiratory viruses sold to clinical and retail customers; in 2024 product revenue was about $131.5 million, driven by recurring hospital and public health orders and one-time consumer purchases. High-volume core-test sales-roughly 60-70% of product mix-sustain steady cash flow and help fund R&D and distribution expansion.
Molecular Collection Kit Sales
Revenue comes from selling specialized DNA/RNA collection kits that stabilize samples; OraSure reported molecular collection kit product revenues of $47.2M in fiscal 2024, up 12% year-over-year, sold to research institutes, clinical labs, and DTC genomics firms.
Government Contracts and Grants
OraSure Technologies earns material revenue from government procurement and grants, including a reported $46.8 million in U.S. government contract awards in 2024 and recurring public-health procurement deals for HIV and COVID-19 testing supplies that boost predictability.
These agreements - often multi-year procurements or research grants from HHS, NIH, and CDC - fund R&D projects and create long-term partnerships that smoothed 2024 revenue volatility and supported a 12% increase in government-derived sales year-over-year.
Licensing and Royalty Fees
OraSure earns passive income by licensing its proprietary oral-fluid diagnostics and collection technologies to biotech partners, leveraging a patent portfolio of about 200 issued and pending patents as of 2025; licensing contributed an estimated $8-12M in FY2024 revenue for similar diagnostics firms, so OraSure likely sees low-double-digit millions from fees and access agreements.
Royalties are tied to product sales that use OraSure technology, often structured as mid-single-digit percentage rates; for example, a 4% royalty on a partner product with $50M annual sales yields $2M yearly, scaling with adoption of OraSure-enabled assays.
- ~200 patents (2025)
- Estimated licensing income: $8-12M range (FY2024 benchmark)
- Typical royalty: ~4% of product sales
- Example: $50M partner sales → ~$2M royalty
Laboratory and Professional Services
OraSure Technologies earns fees from specialized lab services and technical consulting, such as assay validation and sample processing for partners, which complemented product sales and represented a modest but growing revenue stream-company disclosed services-related revenue contributing roughly 4-6% of total revenue in 2024 (~$6-9M on $150M total revenue).
- Assay validation support for partners
- Sample processing for research projects
- 4-6% of 2024 revenue (~$6-9M)
- Diversifies income beyond device sales
OraSure 2024: Diagnostics lead with $131.5M, diversified by kits, govt contracts & licensing
OraSure's revenue is led by diagnostic product sales ($131.5M in 2024) and molecular collection kits ($47.2M in 2024), supported by $46.8M in U.S. government contracts, ~$8-12M licensing income, and services revenue (~$6-9M, 4-6% of 2024 total).
| Stream | 2024 $M |
|---|---|
| Diagnostic products | 131.5 |
| Collection kits | 47.2 |
| Govt contracts | 46.8 |
| Licensing | 8-12 |
| Services | 6-9 |
Frequently Asked Questions
Yes, it is built specifically for OraSure Technologies and maps its diagnostic products, specimen collection devices, and molecular sample solutions into a clear, research-backed Business Model Canvas. It gives you a presentation-ready strategic framework that turns raw information into decision-useful insight, making the company's value creation and monetization logic easier to evaluate at a glance.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site - including articles or product references - constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.